基法林A119-159 (penKid) 和高心血管风险稳定患者的死亡率
Matthias Rau1, Berkan Kurt1, Oliver Hartmann2
1Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Clinical kidney journal
|January 10, 2025
概括
基法林A 119-159 (penKid) 在未幸存者中显示出更高的水平,并预测高风险心血管患者的死亡率. 将penKid添加到现有的功能估计中,可以显著改善死亡率预测.
科学领域:
- 生物标志物发现发现
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 基法林A 119-159 (penKid) 是一种用于评估功能的新型血液生物标志物.
- penKid独立地与恶化功能和死亡率有关.
- 基于penKid的估计膜过率方程 (eGFRPENK-Crea) 优于目前基于肌素的方程.
研究的目的:
- 评估penKid和eGFRPENK-Crea对所有原因死亡率的预测值.
- 评估高心血管风险稳定患者的死亡率预测.
主要方法:
- 在615名稳定的患者中评估了循环penKid水平.
- 在3年内跟踪患者以确定全因死亡率.
- 利用考克斯回归分析来评估与死亡率的关联.
主要成果:
- 与幸存者相比,在未幸存者中观察到更高的penKid水平 (P < .0001).
- 无论是penKid还是eGFRPENK-Crea都与全因死亡率有显著的关联.
- penKid为预测死亡率的eGFRCKD-EPI 2021模型提供了显著的附加值 (Delta χ2 5.81,P <.00001).
结论:
- 在3年随访期间,penKid水平和eGFRPENK-Crea与全因死亡率有关.
- 将penKid添加到eGFRCKD-EPI 2021显著提高了高风险心血管患者的死亡率预测.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
56
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
56
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147